Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C514S634000, C514S637000, C514S689000, C436S086000, C436S111000, C436S128000, C544S264000, C544S276000, C544S277000, C544S319000, C544S321000, C544S323000, C544S326000, C544S332000, C544S335000, C564S237000, C564S244000, C564S305000, C568S042000, C568S043000, C568S308000, C568S329000, C568S331000, C568S335000, C568S337000
Reexamination Certificate
active
06906076
ABSTRACT:
The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.
REFERENCES:
patent: 5574040 (1996-11-01), Bukrinsky et al.
patent: 5620983 (1997-04-01), Bukrinsky et al.
patent: 5703086 (1997-12-01), Bukrinsky et al.
patent: 5733932 (1998-03-01), Bukrinsky et al.
patent: 5808068 (1998-09-01), Pan et al.
patent: 5840305 (1998-11-01), Bukrinsky et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 5840893 (1998-11-01), Bukrinsky et al.
patent: 5849793 (1998-12-01), Pan et al.
patent: 6297253 (2001-10-01), Bukrinsky et al.
patent: 6649797 (2003-11-01), Bukrinsky et al.
Kalderon, et al., “A Short Amino Acid Sequence Able to Specify Nuclear Location”, Cell, 39, 499-509 (1984—Part 2).
Dingwall, et al., “The Nucleoplasmin Nuclear Location Sequence is Larger and More Complex than that of SV-40 Large T Antigen”, J. Cell Biol., 107, 841-849 (1988).
Yeh, et al., “The Arginine-Rich Domain of Hepatitis B Virus Precore and Core Proteins Contains a Signal for Nuclear Transport”, J. Virol., 64, 12, 6141-6147 (1990).
Zacksenhaus, et al., “A Bipartite Nuclear Localization Signal in the Retinoblastoma Gene Product and Its Importance for Biological Activity”, Mol. Cell. Biol., 13, 8, 4588-4599 (1993).
Bukrinsky, et al., “A Nuclear Localization Signal Within HIV-1 Matrix Protein that Governs Infection of Non-Dividing Cells”, Nature, 365, 666-669 (1993).
Goldfarb, et al., “Synthetic Peptides as Nuclear Localization Signals”, Nature, 322, 641-644 (1986).
Lanford, “Induction of Nuclear Transport with a Synthetic Peptide Homologous to the SV40 T Antigen Transport Signal”, Cell, 46, 575-582 (1986).
Adam, et al., “Identification of Specific Binding Proteins for a Nuclear Location Sequence”, Nature, 337, 276-279 (1989).
Robbins, et al., “Two Interdependent Basic Domains in Nucleoplasmin Nuclear Targeting Sequence: Identification of a Class of Bipartite Nuclear Target Sequence”, Cell, 64, 615-623 (1991).
Görlich, et al., “Two Different Subunits of Importin Cooperate to Recognize Nuclear Localization Signals and Bind Them to the Nuclear Envelope”, Curr. Biol., 5, 4, 383-392 (1995).
Radu, et al., “Identification of a Protein Complex that is Required for Nuclear Protein Import and Mediates Docking of Import Substrate to Distinct Nucleoporines”, Proc. Natl. Acad. Sci., 92, 1769-1773 (1995).
Adam, et al., “Cytoslic Proteins that Specifically Bins Nuclear Location Signals are Receptors for Nuclear Import”, Cell, 66, 837-847 (1992).
Rexach, et al., “Protein Import Into Nuclei: Association and Dissociation Reactions Involving Transport Substrate, Transport Factors, and Nucleoporins”, Cell, 83, 683-692 (1995).
Moore, et al., “Purification of a Ran-Interacting Protein that is Required for Protein Import into the Nucleus”, Proc. Natl. Acad. Sci., 91, 10212-10216 (1994).
Nerhbass, et al., “Role of the Nuclear Transport Factor p10 in Nuclear Import”, Science, 272, 120-122 (1996).
Dabauvalle, et al., “Inhibition of Nuclear Accumulation of Karyophilic Proteins in Living Cells by Microinjection of the Lectin Wheat Germ Agglutinin”, Exp. Cell Res., 174, 291-296 (1988).
Sterne-Marr, et al., “O-Linked Glycoproteins of the Nuclear Pore Complex Interact with a Cytosolic Factor Required for Nuclear Protein Import”, J. Cell Biol, 116, 2, 271-280 (1992).
Melchior, et al., “Inhibition of Nuclear Protein Import by Nonhydrolyzable Analogues of GTP and Identification of the Small GTPase Ran/TC4 as an Essential Transport Factor”, J. Cell Biol., 123, 6, Part 2, 1649-1656 (1993).
Weinberg, et al., “Productive Human Immunodeficiency Virus Type 1 (HIV-1) Infection of Nonproliferating Human Monocytes”, J. Exp. Med., 174, 1477-1482 (1991).
Humphries, et al., “Requirement for Cell Division for Initiation of Transcription of Rous Sarcoma Virus RNA”, J. Virol., 14, 3, 531-546 (1974).
Stevenson, et al., “HIV-1 Replication is Controlled at the Level of T Cell Activation and Proviral Integration”, EMBO J., 9, 5, 1551-1560 (1990).
Bukrinsky, et al., “Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection”, Science, 254, 423, Science (1991).
Zack, et al., “Incompletely Reverse-Transcribed Human Immunodeficiency Virus Type 1 Genomes in Quiescent Cells Can Function as Intermediates in the Retroviral Life Cycle”, J. Virol., 66, 3, 1717-1725 (1992).
Schnittman, et al., “The Reservoir for HIV-1 in Human Peripheral Blood is a T Cell That Maintains Express of CD4”, Science, 245, 305-308 (1989).
Brinchmann, et al., “Few Infected CD4+T Cells but a High Proportion of Replication-Competent Provirus Copies in Asymptomatic Human Immunodeficiency Virus Type 1 Infection”, J. Virol., 65, 4, 2019-2023 (1991).
Chapel, et al., “Differential Human Immunodeficiency Virus Expression in CD4+Cloned Lymphoscytes: From Viral Latency to Replication”, J. Virol., 66, 6, 3966-3970 (1992).
Keonig, et al., “Detection of AIDS Virus in Marcrophages in Brain Tissue from AIDS Patients with Encephalopathy”, Science, 233, 1089-1093 (1986).
Wiley, et al., “Cellular Localization of Human Immunodeficiency Virus Infection Within the Brains of Acquired Immune Deficiency Syndrome Patients”, Proc. Natl. Acad. Sci., 83, 7089-7093 (1986).
Price, et al., “The Brain in AIDS: Central Nervous System HIV-1 Infection and AIDS Dementia Complex”, Science, 239, 586-592 (1988).
Giulian, et al., “Secretion of Neurotoxins by Mononuclear Phagocytes Infected with HIV-1”, Science, 250, 1593-1596 (1990).
Fauci, et al., “Immunopathogenic Mechanisms in Human Immunodeficiency Virus (HIV) Infection”, Ann. Int. Med., 114, 8, 678-693 (1991).
Pantaleo, et al., “HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinically Latent Stage of Disease”, Nature, 362, 355-358 (1993).
Zack, “HIV-1 Entry Into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure”, Cell, 61, 213-222 (1990).
Spina, et al., “The Importance of nef in the Induction of Human Immunodeficiency Virus Type 1 Replication from Primary Quiescent CD4 Lymphocytes”, J. Exp. Med., 179, 115-113 (1994).
Miller, et al., “The Human Immunodeficiency Virus-1 nef Gene Product: A Positive Factor for Viral Infection and Replication in Primary Lymphocytes and Macrophages”, J. Exp. Med., 101-113 (1994).
von Schwedler, et al., “The Nuclear Localization Signal of the Matrix Protein of Human Immunodeficiency Virus Type 1 Allows the Establishment of Infection in Macrophages and Quiescent T Lymphocytes”, Proc. Natl. Acad. Sci., 91, 6992-6996 (1994).
Brown, et al., “Correct Integration of Retroviral DNA in Vitro”, Cell, 49, 347-356 (1987).
Emerman, et al., “HIV-1 Infection of Non-Dividing Cells”, Nature, 369, 107-108 (1994).
Heinzinger, et al., “The Vpr Protein of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization of Viral Nucleic Acids in Nondividing Host Cells”, Proc. Natl. Acad. Sci., 91, 7311-7315 (1994).
Gulizia, et al., “Reduced Nuclear Import of Human Immunodeficiency Virus Type 1 Preintegration Complexes in the Presence of a Prototypic Nuclear T
Berger Bradley
Bukrinsky Michael I.
Cerami Anthony
Ulrich Peter
Cytokine Pharmasciences, Inc.
DLA Piper Rudnick
Gray Cary US LLP
Kelber Steven B.
Raymond Richard L.
LandOfFree
Compounds and methods of use to treat infectious diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods of use to treat infectious diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods of use to treat infectious diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504809